Galecto to Highlight GB3226 Program at ASH 2025
Galecto, Inc. (GLTO)
Company Research
Source: GlobeNewswire
Two Presentations at ASH 2025 to highlight preclinical data and clinical development plans for GB3226, a novel dual ENL-YEATS and FLT3 inhibitor for the treatment of acute myeloid leukemia (AML) BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, today announced that preclinical data and clinical development plans for its investigational candidate GB3226 will be featured in two poster presentations at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 6 – 9, 2025, in Orlando, Florida. GB3226 is a first-in-class, orally bioavailable, small-molecule inhibitor designed to simultaneously target ENL-YEATS, an epigenetic driver of leukemogenesis, and FLT3, a key oncogenic kinase mutated in approximately 30% of adult AML patients. The unique dual inhibition of these pathways may offer greater therapeutic b
Show less
Read more
Impact Snapshot
Event Time:
GLTO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLTO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLTO alerts
High impacting Galecto, Inc. news events
Weekly update
A roundup of the hottest topics
GLTO
News
- Galecto (NASDAQ:GLTO) was upgraded by analysts at Guggenheim to a "strong-buy" rating.MarketBeat
- Galecto (NASDAQ:GLTO) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.MarketBeat
- Galecto (NASDAQ:GLTO) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=GLTO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> MarketBeat
- Galecto (NASDAQ:GLTO) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=GLTO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> frMarketBeat
- This Penny Stock Just Quadrupled. Should You Buy It Now? [Yahoo! Finance]Yahoo! Finance
GLTO
Sec Filings
- 11/21/25 - Form D
- 11/17/25 - Form 3
- 11/17/25 - Form SCHEDULE
- GLTO's page on the SEC website